uveal melanoma
Conditions
Interventions
None listed
Sponsors
National Institute for Quantum Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cases of choroidal malignant melanoma treated with carbon ion beam therapy at QST Hospital from April 1992 to October 2021, and cases treated with photon beam therapy using stereotactic irradiation with CyberKnife at Yonsei University Severance Hospital
Exclusion criteria
Exclusion criteria: (i) Cases in which the research subject or his/her representative refuses the use of clinical data for this study. (ii) Recurrent cases, metastatic cases, cases with a history of irradiation to the head and neck region, and cases in which the comorbid invasive cancer has not remained disease-free for at least 3 years (excluding malignant tumors that do not significantly affect prognosis, such as thyroid cancer, MALT lymphoma, basal cell carcinoma of the skin, and early stage prostate cancer). (iii) Patients who are lost to follow-up without at least one post-treatment follow-up visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control rate, adverse events, recurrence-free survival, eye preservation rate | — |
Countries
Japan,Asia(except Japan)
Contacts
Public ContactMasaru Wakatsuki
QST Hospital, National Institute for Quantum Science and Technology Department of Diagnostic Radiology and Radiation Oncology
Outcome results
None listed